Baird analyst Brian Skorney reiterates Amgen (NASDAQ:AMGN) with a Underperform and maintains $215 price target.
Baird Reiterates Underperform on Amgen, Maintains $215 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.